May 2026 Research Update

Across this months papers, the clearest pattern was that daratumumab-based treatment was linked to deeper and faster control of the underlying abnormal blood protein and to better organ outcomes, compared with similar treatment without daratumumab. Evidence was strongest in a large randomized trial in newly diagnosed patients, with supporting (but smaller and less definitive) real-world and single-center studies. In contrast, an added antibody aimed at clearing amyloid deposits (anselamimab) did not improve the main heart-related outcome overall, with mixed results by light-chain type. [1] [2] [3] [4]

In the phase 3 ANDROMEDA trial of 388 newly diagnosed patients, daratumumab added to bortezomib, cyclophosphamide, and dexamethasone led to a much higher complete blood response (59.5% vs 19.2%) and a faster time to that response. Over a median follow-up of about 5 years, people receiving daratumumab also had better overall survival and longer time without major organ worsening, and heart and kidney responses were reported to be about 2 to 3 times higher. Safety was described as consistent with what is already known for these medicines. [1]

A retrospective single-center study from Japan (43 patients) reported higher blood and organ response rates and improved overall survival with daratumumab-containing regimens compared with non-daratumumab regimens, and most evaluated very advanced (stage IV) patients had organ responses when therapy started at reduced intensity and was gradually increased. Because this was not randomized and was done at one center, differences between groups could have influenced results. [2]

In frail, non-transplant-eligible patients with kidney (renal) AL amyloidosis, a single-center comparison of consecutive cohorts suggested daratumumab alone produced higher blood responses (92.8% vs 57.1%) and higher kidney responses (71.4% vs 35%) than earlier bortezomib-based treatment, with similar rates of major infections (14% vs 18%). Repeat kidney biopsies more often showed stabilization or regression of amyloid in daratumumab-treated patients (62% vs 20%), but the study was small and non-randomized, so it needs confirmation. [3]

The CARES randomized trial tested anselamimab (an antibody designed to bind amyloid deposits) added to standard anti-plasma cell therapy in 406 newly diagnosed patients with advanced heart involvement (stage IIIa/IIIb). The trial did not improve the main combined outcome of death and cardiovascular hospitalizations in the overall group, and there was no benefit in the lambda light-chain group; in a smaller kappa subgroup (72 people), fewer deaths and cardiovascular hospitalizations and better quality of life were reported. Safety was similar to placebo. [4]

Three single-patient case reports described improvement after treatments tailored to the suspected source of the disease: daratumumab-based therapy (including after an initial regimen did not work) with transplant and maintenance in one patient with extensive lymph node involvement, daratumumab as first treatment after a severe spleen event revealed multisystem disease in another patient, and zanubrutinib for an underlying lymphoplasmacytic lymphoma in a patient with major gastrointestinal symptoms plus supportive digestive care. Because each report describes one person, these outcomes may not apply to others. [5] [6] [7]

One additional case report focused on liver involvement linked to lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: after endoscopic ultrasound-guided liver biopsy confirmed AL amyloidosis, the patient was treated with melphalan and dexamethasone and had reduced abnormal blood markers and modest improvement in liver tests. A small liver hematoma after the procedure resolved over 2 months. [8]

For patients and caregivers, this set of studies mainly strengthens the evidence that daratumumab-containing regimens can improve the chance of a deep blood response and can translate into better organ outcomes, including heart and kidney responses, with the strongest support coming from a large randomized trial. The anselamimab study matters as background for future research: it did not help the overall group with advanced heart involvement, and the reported benefit was limited to a smaller kappa subgroup, so it remains uncertain who (if anyone) would reliably benefit. The case reports add real-world examples (including unusual presentations and disease linked to lymphoma), but they cannot predict results for most people because they describe individual situations.

Across this set of papers, earlier diagnosis of AL amyloidosis centered on recognizing heart involvement sooner and reducing avoidable diagnostic uncertainty. A guideline emphasized that stage at diagnosis strongly relates to outcomes, while clinical studies and case reports highlighted both newer tools and common imaging pitfalls. Overall, the direction was toward using multiple inputs (clinical data plus imaging, and confirmatory imaging when needed) rather than relying on a single test. [9] [10] [11] [12] [13] [14]

A British Society for Haematology guideline aimed to help different clinics (blood, heart, nerve, kidney, and general) raise suspicion earlier, because outcomes differ greatly by stage. It reported about 80% 5-year survival for early-stage disease with contemporary treatment, compared with less than 30% for advanced disease. [9]

In a retrospective multicenter study using a global multiethnic registry, an artificial intelligence model that combined heart ultrasound features with basic clinical and lab information identified cardiac amyloidosis more accurately than an ultrasound-only model. The combined model had an area-under-the-curve of 0.94 and classified all cases, while the ultrasound-only model was indeterminate in 9% of cases. The study also reported improved sensitivity for detecting light-chain related cardiac amyloidosis while keeping good performance across different subtypes and control groups. [10]

Two papers focused on a specific scan used in amyloidosis workups, technetium pyrophosphate imaging, and how it can be misread if only planar images are used. One case report described how blood-pool activity could look like heart muscle uptake on planar images, while SPECT confirmed true heart muscle uptake; the authors noted that published literature suggests 10% to 20% of AL amyloidosis patients may show true uptake, which can complicate interpretation. A related commentary argued that an earlier report likely misinterpreted blood-pool activity as true uptake, and emphasized confirmatory imaging (ideally SPECT/CT with expert interpretation) rather than relying on planar imaging alone. [11] [12]

Several single-patient case reports illustrated how clinicians may use more than one heart test when AL amyloidosis is suspected, especially when some tests are impractical or not available. One report described severe heart failure and multi-organ involvement where echocardiography strain results and heart MRI supported diagnosis, later confirmed by kidney and tongue biopsies. Another report in a patient with IgA lambda multiple myeloma described a working diagnosis of AL cardiac amyloidosis supported by heart imaging and blood markers when biopsy or certain scans were impractical, with biomarker improvement despite persistent structural heart changes. [13] [14]

For patients and caregivers, these papers mainly provide context for why the diagnostic path can involve several steps and different types of heart testing. The guideline underscores that earlier-stage diagnosis is linked to much better survival than later-stage diagnosis, which is why clinicians aim to recognize the condition sooner. The artificial intelligence study suggests that combining routine clinical information with heart ultrasound data may help flag cardiac amyloidosis more reliably in the future, but it does not by itself define how any one person should be evaluated. The case reports and commentary highlight a practical uncertainty: some scans can look positive for reasons unrelated to true heart muscle involvement, so confirmatory imaging and expert interpretation can matter, and access to tests may vary by setting. [9] [10] [11] [12] [13] [14]

Across these studies in newly diagnosed amyloidosis, the clearest pattern was that measurable organ status at baseline and early changes after starting therapy helped predict longer-term outcomes. Kidney recovery was more likely when the underlying abnormal blood protein improved early and kidney involvement was less advanced, while heart-related imaging and rhythm monitoring added information about survival and arrhythmia risk. These are prediction tools, not guarantees for any one person. [15] [16] [17]

For kidney outcomes, a retrospective study of 350 newly diagnosed AL amyloidosis patients treated with anti-plasma cell therapy defined a "deep" kidney response based on a large drop in urine protein. Deep kidney response was more likely when patients reached a very good blood-protein response within 6 months, started with a higher level of the abnormal blood marker, had a kappa type, had lower kidney stage, and had an autologous stem cell transplant as part of initial therapy. In plain terms, earlier control of the disease-driving protein and less advanced kidney involvement went along with a better chance of larger kidney improvement over time. [15]

For heart-related outcomes in AL cardiac amyloidosis, a prospective study of 142 newly diagnosed patients found that a three-dimensional ultrasound measure of right heart pumping strength (right ventricular ejection fraction) predicted overall survival even after accounting for other clinical factors. A cutoff of 40% separated higher-risk from lower-risk groups, and adding this right-heart measure improved a model that already included a left-heart strain measure. In plain terms, how well the right side of the heart pumps can provide additional survival information beyond commonly used heart measurements. [16]

A separate prospective single-center study used implantable loop recorders in 110 treatment-naive patients with either transthyretin amyloid cardiomyopathy or AL cardiac amyloidosis to track rhythm problems and relate them to heart imaging. Rhythm problems differed by amyloid type, with more slow-heart-rhythm events and new atrial fibrillation in transthyretin disease than in AL cardiac amyloidosis, and greater amyloid burden on heart MRI plus baseline conduction changes predicting later rhythm events. In plain terms, rhythm monitoring and MRI estimates of amyloid load helped identify who was more likely to develop certain heart rhythm problems, and the rhythm at the end of life differed somewhat by subtype in this cohort. [17]

For patients and caregivers, this group of studies helps explain why clinicians often track both early blood-marker response and organ-specific tests over time: these measurements can help estimate the likelihood of later kidney improvement or heart-related risks in groups of patients. Some measures discussed here (advanced heart ultrasound techniques, heart MRI amyloid burden estimates, and continuous rhythm monitoring) may not be available everywhere, and they do not predict the future perfectly for an individual. It also remains uncertain how best to use these prediction tools to change outcomes, because these studies focused on forecasting risk rather than testing whether acting on the information improves results. [15] [16] [17]

This months papers show that AL amyloidosis can affect multiple organs and may be discovered either because of symptoms or by accident during tests done for other reasons. Across the reports, lung involvement often appeared as nodules on scans, gastrointestinal involvement could be localized and silent, and skin and mouth changes were frequent in a clinic population. Because amyloid type was not always confirmed, there is still uncertainty about how often each pattern applies specifically to AL versus other amyloid types. [18] [19] [20]

In a small, single-center lung series of 12 people with biopsy-proven pulmonary amyloidosis, the most common scan pattern was nodular disease (92%), and half of cases were diagnosed incidentally. Shortness of breath, cough, and fatigue were among the reported symptoms, but management varied, in part because only a minority had amyloid subtyping completed. [18]

A single-patient case report described localized AL-type gastrointestinal amyloidosis found incidentally during colonoscopy in a man in his 40s. After testing did not show whole-body (systemic) involvement, the gastrointestinal findings remained stable for 5 years, and no gastrointestinal symptoms developed during that time. [19]

In a cross-sectional study of 14 people with primary systemic amyloidosis seen for skin or mouth symptoms, bruising-like purple discoloration around the eyes was reported in 92.8%, and tongue involvement was reported in all patients. Waxy skin bumps were also common (78.5%), and 35.7% were described as having myeloma-associated disease, highlighting overlap with plasma cell disorders in some patients. [20]

For patients and caregivers, these studies reinforce that amyloidosis can show up in different body areas, sometimes with noticeable changes (such as easy bruising around the eyes or tongue changes) and sometimes without symptoms (such as lung nodules or localized gut deposits found during other testing). Most evidence here comes from small, single-center descriptions and individual case reports, and some patients were not fully subtyped, so how often these patterns occur in confirmed AL amyloidosis remains uncertain.

Across these papers, access to specialized amyloidosis care came through a mix of strong coordination inside expert centers and real-world barriers that can make getting that care difficult. In parallel, US insurance and medical record data showed that AL amyloidosis care can involve frequent visits, hospital stays, and substantial costs, especially when the heart is more severely involved. Overall, the direction of the evidence points to both practical access hurdles and a high care burden, while the studies do not directly show which access changes improve health outcomes. [21] [22]

In an interview-based study across 17 US specialized amyloidosis centers, stakeholders described best practices that focus on patient-centered coordination, including multidisciplinary teamwork and centralized intake to triage higher-risk patients quickly. Barriers repeatedly mentioned included long travel distances, limits in sharing medical records across systems, and insurance hurdles. Most centers reported involvement in clinical trials, suggesting that access to expert centers may also affect access to research studies. [21]

In a retrospective study of 85 US adults with AL amyloidosis using linked electronic health records and claims, healthcare use was high over 12 months, including hospital, outpatient, office, and emergency visits. The economic burden was heavier in people with advanced heart involvement, where median condition-related costs were reported at about $7,532 per patient per month and all-cause costs at about $17,149 per patient per month. The study also reported long average hospital stays (about 20 days in the advanced group), showing how intensive care can become in advanced disease. [22]

For patients and caregivers, this set of studies mainly helps explain why AL amyloidosis can feel hard to manage even when expert care exists: travel, insurance steps, and record-sharing problems can slow or complicate care, and advanced heart involvement can come with frequent healthcare visits and high costs. These papers describe patterns and barriers rather than testing solutions, so it remains uncertain which specific changes (for example, telemedicine, intake systems, or better data-sharing) most improve day-to-day experience or health outcomes. [21] [22]

Across these papers, misfolding is presented as a problem of both protein chemistry and cell biology. One study points to very small amino-acid changes that can make a light-chain protein less stable and more likely to stick to other copies of itself, while another paper cautions that not all related immune cells carry the same malignant features that lead to harmful light-chain production. [23] [24]

In a lab study using purified recombinant lambda light chains, a short segment in a variable-region loop (CDR1) helped drive aggregation under heat stress. Two specific positions (Ser33 and Tyr34) mattered: changing them (S33D/Y34S) reduced aggregation even though the temperature where the protein unfolded stayed about the same. [23]

The same lab work suggested that one version of the light chain had lower kinetic stability (it fell apart more easily over time), which can leave more unfolded protein available to clump. Once unfolded, aggregation depended strongly on how much protein was present and only weakly on temperature, consistent with multiple molecules assembling together; Tyr34 was linked to aromatic interactions that helped stabilize these assemblies. [23]

A separate commentary focused on which cells carry the key disease features in plasma-cell disorders. It argued that major genetic hallmarks are largely confined to plasma cells, and that rare clonotypic B cells (cells related by shared antibody sequence) may not have the same malignant potential, which could confuse minimal residual disease tests by creating false-positive signals. [24]

For patients, this set of papers mainly adds background on why the harmful protein can differ from person to person: tiny sequence differences may change how easily a light chain can clump, and the main disease-driving changes may be concentrated in plasma cells that produce the protein. These are not treatment studies, and the protein work was done in the lab under artificial stress conditions, so it does not directly predict what will happen in any one individual. It also remains uncertain how well these specific sequence features explain organ damage in real-world AL amyloidosis, but they help frame why both the protein itself and the cell producing it matter.